These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16750364)

  • 61. 5-HT2C ligands: recent progress.
    Monck NJ; Kennett GA
    Prog Med Chem; 2008; 46():281-390. PubMed ID: 18381128
    [No Abstract]   [Full Text] [Related]  

  • 62. Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study.
    Invernizzi RW; Pierucci M; Calcagno E; Di Giovanni G; Di Matteo V; Benigno A; Esposito E
    Neuroscience; 2007 Feb; 144(4):1523-35. PubMed ID: 17161544
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists.
    Alcalde E; Mesquida N; López-Pérez S; Frigola J; Mercè R
    J Med Chem; 2009 Feb; 52(3):675-87. PubMed ID: 19159187
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of novel serotonin 2C receptor ligands by sequential virtual screening.
    Ahmed A; Choo H; Cho YS; Park WK; Pae AN
    Bioorg Med Chem; 2009 Jul; 17(13):4559-68. PubMed ID: 19464901
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
    Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
    Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discovery of a lead series of potent benzodiazepine 5-HT
    Ren A; Zhu X; Feichtinger K; Lehman J; Kasem M; Schrader TO; Wong A; Dang H; Le M; Frazer J; Unett DJ; Grottick AJ; Whelan KT; Morgan ME; Sage CR; Semple G
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126929. PubMed ID: 31952960
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors.
    Eliás O; Agai-Csongor E; Domány G; Keserű GM; Gere A; Kiss B; Hellinger E; Vastag M; Gyertyán I
    Bioorg Med Chem Lett; 2014 May; 24(9):2118-22. PubMed ID: 24717153
    [TBL] [Abstract][Full Text] [Related]  

  • 69. m-CPP induced hypolocomotion does not interfere in the assessment of memory functions in rats.
    Khaliq S; Irfan B; Haider S; Haleem DJ
    Pak J Pharm Sci; 2008 Apr; 21(2):139-43. PubMed ID: 18390444
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
    J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
    Green MP; McMurray G; Storer RI
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
    Prisinzano T; Dukat M; Law H; Slassi A; MacLean N; DeLannoy I; Glennon RA
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4697-9. PubMed ID: 15324890
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effects of metergoline and 8-OH-DPAT injections into arcuate nucleus and lateral hypothalamic area on feeding in female rats during the estrous cycle.
    Steffens SM; da Cunha IC; Beckman D; Lopes AP; Faria MS; Marino-Neto J; Paschoalini MA
    Physiol Behav; 2008 Oct; 95(3):484-91. PubMed ID: 18694771
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist.
    Vidal B; Nueda A; Esteve C; Domenech T; Benito S; Reinoso RF; Pont M; Calbet M; López R; Cadavid MI; Loza MI; Cárdenas A; Godessart N; Beleta J; Warrellow G; Ryder H
    J Med Chem; 2007 May; 50(11):2732-6. PubMed ID: 17469811
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disposition and metabolism of almotriptan in rats, dogs and monkeys.
    Aubets J; Cardenas A; Salva M; Jansat JM; Martinez-Tobed A; Palacios JM
    Xenobiotica; 2006 Sep; 36(9):807-23. PubMed ID: 16971345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
    Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
    Imanishi M; Tomishima Y; Itou S; Hamashima H; Nakajima Y; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
    J Med Chem; 2008 Mar; 51(6):1925-44. PubMed ID: 18307290
    [TBL] [Abstract][Full Text] [Related]  

  • 78. APD-356 (Arena).
    Jandacek RJ
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1051-6. PubMed ID: 16259227
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.
    Lacombe P; Deschênes D; Dubé D; Dubé L; Gallant M; Macdonald D; Mastracchio A; Perrier H; Charleson S; Huang Z; Laliberté F; Liu S; Mancini JA; Masson P; Salem M; Styhler A; Girard Y
    Bioorg Med Chem Lett; 2006 May; 16(10):2608-12. PubMed ID: 16516471
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
    Pike KG; Allen JV; Caulkett PW; Clarke DS; Donald CS; Fenwick ML; Johnson KM; Johnstone C; McKerrecher D; Rayner JW; Walker RP; Wilson I
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3467-70. PubMed ID: 21515051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.